Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
Lisa KobrynskiDepartment of Pediatrics, Emory University, Atlanta, GA, USAAbstract: Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurr...
Enregistré dans:
Auteur principal: | Kobrynski L |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2012
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/5352b791509b4c489e7611f4de1324f9 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF PRIMARY IMMUNODEFICIENCY DISEASES (PID) AND EARLY DIAGNOSIS OPTIONS
par: I. A. Korsunskiy, et autres
Publié: (2017) -
Immunoglobulin G4-related kidney disease: Pathogenesis, diagnosis, and treatment
par: Ke Zheng, et autres
Publié: (2017) -
Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
par: Luca Gentile, et autres
Publié: (2021) -
Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia.
par: S Shahzad Mustafa, et autres
Publié: (2021) -
A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
par: Wells AF, et autres
Publié: (2014)